This novel targeted therapy has the advantage of sequentially targeting major processes involved in melanoma development with higher efficiency, by using both the advantage of superior tumor targeting of LCL and EVs, as well as the higher affinity toward M2 macrophages given by IL-13 conjugation of the liposomal formulation. The gene discussed is IL13; the disease is melanoma.